Newsroom | 7893 results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its innovative pulsed field ablation (PFA) device—the Globe PF System. These pivotal findings from the PULSAR IDE study were announced at the Heart Rhythm Society (HRS) meeting in San Diego1, highlighting the safety and efficacy data of the Globe PF System, which is currently...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717...

CLICHY, France--(BUSINESS WIRE)--CorWave, a medical device company dedicated to the fight against heart failure, announces new preclinical results of its implantable heart pump. CorWave’s in vivo studies demonstrated the pump’s successful operation for six months. Additionally, nine chronic ovine implants were conducted for 60 days, without chronic anticoagulant therapy. There was no device failure during the studies and no sign of thrombosis at explant. The CorWave device operated in pulsatile...

LOS ANGELES--(BUSINESS WIRE)--The GRAMMY Museum® Grant Program announced today that $200,000 in grants will be awarded to 15 recipients in the United States to help facilitate a range of research on a variety of subjects, as well as support a number of archiving and preservation programs. "The GRAMMY Museum and Recording Academy® have continued their partnership to provide fundamental funding for music research and preservation projects across the United States and Canada. We are incredibly ins...

SANTA CLARA, Calif. & NEW YORK--(BUSINESS WIRE)--HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana is expanding beyond diagnostic ECG-AI technology into perioperative and acute cardiac care and has welcomed Boston Scientific as an investor....

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators from leading transplant centers, will present the latest advancements in clinical evidence supporting its transplant care solutions at the Inter...

IRVING, Texas--(BUSINESS WIRE)--The latest Medical Device Tech Watch also reviews emerging trends in cardiovascular and peripheral interventions....

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT p...